Key Highlights: Implications: By preparing manufacturing and technology transfer now, Dr. Reddy’s can help expand long‑acting PrEP options beyond daily pills and six‑monthly injections, po...
Key Highlights: Implications: Cipla’s licensing deal adds a potential new HER2-targeted cancer treatment to its pipeline in India, South Africa and five other emerging markets, stren...
